1
results found
Background: Among F8 mutation types, main determinants of inhibitor development after replacement therapy in Hemophilia A, nonsense mutations display wide variation in the associated risk. Molecular m...
F8 PTCs
Hemophilia A
translational readthrough
inhibitory antibody
peptide MHCII affinity
personalized medicine
SinoXiv